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Abstract: Trastuzumab in combination with chemotherapy has become a standard of care 
for patients with HER2+ breast cancer. The cost of therapy, however, can limit patient access 
to trastuzumab in areas with limited financial resources for treatment reimbursement. This 
study examined access to trastuzumab and identified potential barriers to its use in the United 
States, Mexico, Turkey, Russia and Brazil via physician survey. The study also investigated 
if the availability of a biosimilar to trastuzumab would improve access to and use of HER2 
monoclonal antibody therapy. Across all countries, a subset of oncologists reported barriers 
to the use of trastuzumab in a neoadjuvant, adjuvant or metastatic setting. Common barriers 
to the use of trastuzumab included issues related to insurance coverage, drug availability and 
cost to the patient. Overall, nearly half of oncologists reported that they would increase the 
use of HER2 monoclonal antibody therapy across all treatment settings if a lower cost 
biosimilar to trastuzumab were available. We conclude that the introduction of a biosimilar 
to trastuzumab may alleviate cost-related barriers to treatment and could increase patient 
access to HER2-directed therapy in all countries examined. 








Breast cancer is the most common cancer among women and is the primary cause of cancer death 
among women worldwide, accounting for ~522,000 deaths in 2012 [1]. Incidence rates differ throughout 
the world, but rates are highest in developed countries [1]. In the United States (US), for example, over 
235,000 new cases of invasive breast cancer are expected in 2014 [2]. Survival rates also vary across 
regions; rates are over 80% in North America, Australia, Sweden, Finland and Japan, ~60% in Brazil, 
Poland and Slovakia, but below 40% in Algeria [3]. Low survival rates in less-developed countries 
may be explained by a lack of early detection programs and poor access to the newest therapies [4]. 
Even in the U.S., despite advanced detection and treatment programs, it is estimated that 
approximately 40,000 women will die from breast cancer in 2014 [2]. 
Trastuzumab, marketed under the trade name, Herceptin® (Genentech, South San Francisco, CA, 
USA), is a monoclonal antibody directed against the human epidermal growth factor receptor 2  
protein (HER2) [5]. Trastuzumab is indicated as an adjuvant treatment for HER2-overexpressing breast 
cancer and for the treatment of metastatic HER2-overexpressing breast cancer [5,6]. In three large-scale, 
randomized, open-label trials in women with HER2+ breast cancer, treatment with adjuvant trastuzumab 
resulted in a 52% increase in disease-free survival [7,8] and a 33% reduction in risk of death [8] relative 
to chemotherapy alone. Likewise, the addition of trastuzumab to standard chemotherapy in patients  
with first-line metastatic HER2+ breast cancer resulted in an increase in time to disease progression 
and resulted in a 20% decrease in the risk of death [9]. Trastuzumab, in combination with pertuzumab  
and docetaxel, has also shown efficacy in women with locally-advanced, inflammatory or early  
HER2+ breast cancer [10]. 
Biologics, such as trastuzumab, are complex medicines developed from living organisms [11].  
The cost associated with biologic therapy may limit patient access to these medicines in areas with 
limited financial resources for treatment reimbursement. Decreasing the cost of therapy and, as a result, 
improving access to biologic treatments is a priority in such areas. The use of biosimilars may be one 
approach to increase access to specific biologic therapies by offering a comparable, but more 
affordable, alternative. The term “biosimilar” refers to a biologic drug that is developed to be highly 
similar, in terms of safety, purity and potency, to an existing licensed reference biologic [11–13]. 
Biosimilars treat the same conditions as the reference biologic, but are commonly priced 25% to 30% 
less [12,14]. The use of biosimilars is expected to grow substantially in the near future as biologic 
patents expire [12,13]. In anticipation of this growth and in recognition of the potential that biosimilars 
have to increase access to biologic therapy, the Biologics Price Competition and Innovation Act of 
2009 (part of the Patient Protection and Affordable Care Act) and the European Medicines Agency 
Committee for Medicinal Products for Human Use have established guidelines for the development and 
streamlined approval of biosimilars in the U.S. [15] and the EU [16], respectively. 
Access to trastuzumab may be a barrier to effective treatment for a large group of patients. With this 
issue in mind, the objectives of the current study were to examine the level of access that physicians and 
patients in the U.S., Mexico (MEX), Turkey (TUR), Russia (RUS) and Brazil (BRZ) have to Herceptin 
(trastuzumab) and to identify potential barriers that may prevent its use in the treatment of HER2+ 
breast cancer. An additional objective of this study was to determine whether the introduction of a 
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biosimilar to trastuzumab would increase access to and use of HER2 monoclonal antibody therapy in 
these countries. 
2. Experimental Section 
2.1. Approach 
A questionnaire was designed to evaluate the access to and usage of trastuzumab by oncologists in the 
U.S., BRZ, MEX, RUS and TUR. Recruiters who were familiar with each country’s healthcare system 
and culture engaged physicians. Physicians were identified from proprietary databases, association lists, 
telephone directories and other commercially available sources. Alternatively, physicians who were 
existing members of a recruiter’s online community could request to participate in the survey. Physicians 
were invited to participate by telephone or email. Those agreeing to participate were emailed a link to the 
automated online survey. A short screener survey was used to identify physicians for the main survey.  
To participate, physicians must have been a full-time hematologist/medical oncologist (practicing at 
least 30 h/week), in practice between 2 and 30 years, spent at least 75% of the time in direct patient 
care and have a practice consisting of a combination of hospital and office based (U.S. only), and at 
least 20% of their cancer patients must have been diagnosed with breast cancer (at least 10% of those 
patients being HER2+). 
The goal was to survey 500 physicians; 200 in the U.S. and 75 each in BRZ, MEX, RUS and  
TUR. In total, 7,994 physicians were invited to participate in the survey (U.S. = 1,530, BRZ = 3,848, 
MEX = 1,529, RUS = 702, TUR = 385). The short screener survey was failed by 351 physicians, and 
another 16 physicians started the main survey, but discontinued without completing. Once a country 
achieved its pre-specified goal, the survey was no longer administered in that country, regardless of the 
number of invited physicians remaining/willing to participate. Using these sample sizes, the margins of 
error at the 95% confidence level were ±4.4% (overall), ±6.9% (U.S.; n = 200) and ±11.3% (all other 
countries; n = 75). 
2.2. Survey Details 
The questionnaire focused on HER2+ breast cancer patients. Specific questions were related to: 
breast cancer disease categories; types of patient insurance; factors considered when making treatment 
decisions; use of treatment guidelines; use of trastuzumab; barriers to the use of trastuzumab; and the 
potential use of a less expensive biosimilar version of trastuzumab if it were available. Questions were 
answered in a variety of forms, including: yes/no; percentage; 5- or 7-point Likert scale; and select all 
that apply. In some cases, participants were offered a text box to further explain their answers. The 
survey was expected to take ~10 min to complete, and participants received an honorarium upon 
completion. The survey was administered from December, 2012, to January, 2013. 
  




3.1. Breast Cancer Patient Population 
Physicians reported that 41% (range, 36%–53%) of their patients had breast cancer, and nearly  
one-third (range, 25%–35%) of the cancers were characterized as HER2+ (Table 1). HER2+ breast 
cancer patients utilized different types of insurance coverage across markets. More than 50% of 
patients, particularly those in MEX, TUR and RUS, had government-funded insurance (overall = 55%, 
U.S. = 37%, BRZ = 34%, MEX = 69%, TUR = 93%, RUS = 74%). Twenty-two percent of patients 
received private medical insurance through their employer (U.S. = 38%, BRZ = 26%, MEX = 8%,  
TUR = 4%, RUS = 7%), while 18% (U.S. = 20%, BRZ = 36%, MEX = 16%, TUR = 2%, RUS = 8%) 
paid for their own private insurance. Patients in MEX and RUS were the most likely to pay for  
medical expenses out of pocket, compared with other markets (overall = 5%, U.S. = 5%, BRZ = 5%, 
MEX = 8%, TUR < 1%, RUS = 11%). 
Table 1. Description of the breast cancer patient population. 
Type of Cancer Overall U.S. BRZ MEX TUR RUS 
Breast, % of all cancer patients 41 36 41 53 36 51 
HER2+, % of breast cancer patients 31 35 27 28 25 33 
U.S., United States; BRZ, Brazil; MEX, Mexico; TUR, Turkey; RUS, Russia. 
3.2. Factors Considered When Treating HER2+ Breast Cancer Patients 
Physicians reported that clinical treatment guidelines (88%), goals of therapy (68%) and 
recommendations from opinion leaders (52%) were the factors most considered when making treatment 
decisions regarding patients with HER2+ breast cancer. These were followed by performance status 
(49%), patient insurance status (39%), patient demographics (25%) and geographic locale (8%). 
National Comprehensive Cancer Network (NCCN) guidelines were regarded as the most influential 
treatment guidelines among all physicians (overall = 66%). NCCN guidelines are considered by 82% 
of all physicians (U.S. = 92%, BRZ = 95%, MEX = 84%, TUR = 97%, RUS = 25%) when treating 
patients. American Society of Clinical Oncology (overall = 58%, U.S. = 47%, BRZ = 89%, MEX = 76%, 
TUR = 61%, RUS = 36%), European Society for Medical Oncology (overall = 56%, U.S. = NA,  
BRZ = 63%, MEX = 36%, TUR = 65%, RUS = 59%) and St. Gallen (overall = 47%, U.S. = NA,  
BRZ = 63%, MEX = 59%, TUR = 32%, RUS = 33%) guidelines were also frequently reported as 
guidelines considered by physicians. National Ministry of Health guidelines were reported by 52% of 
physicians in RUS. 
Physicians were asked whether the clinical guidelines they follow explicitly recommend the use of 
trastuzumab for the treatment of HER2+ breast cancer patients in different clinical settings. Across all 
countries, a majority of physicians reported that trastuzumab is explicitly recommended for use in a 
neoadjuvant setting in HER2+ breast cancer patients (overall = 57%). This was reported by a greater 
number of physicians in the U.S. (66%), TUR (72%) and RUS (56%) and fewer in BRZ (35%) and 
MEX (39%). Across all countries, a majority of physicians reported that trastuzumab is also explicitly 
recommended for use in an adjuvant setting in HER2+ breast cancer patients if the therapy duration is 
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greater than 6 months (overall = 63%). This was reported by a greater number of physicians in the  
U.S. (69%), TUR (81%) and RUS (65%) than in BRZ (49%) and MEX (44%). Finally, a majority of 
physicians reported that trastuzumab is explicitly recommended for use in a metastatic setting in HER2+ 
breast cancer patients. This was consistent for both first line (overall = 68%, U.S. =77%, BRZ = 55%, 
MEX = 49%, TUR = 87%, RUS=56%) and second line (overall = 64%, U.S. = 71%, BRZ = 48%, 
MEX = 41%, TUR = 83%, RUS = 68%) treatment settings. 
3.3. Trastuzumab Usage and Barriers to Treatment 
Physicians were asked to report how frequently (1 = always, 2 = frequently, 3 = not so often, 4 = rarely, 
5 = never) they used trastuzumab in HER2+ breast cancer patients in different clinical settings. In all 
countries, except RUS, a majority of physicians reported always or frequently using trastuzumab in a 
neoadjuvant setting (overall = 73%, U.S. = 78%, BRZ = 80%, MEX = 81%, TUR = 83%, RUS = 33%). 
A majority of physicians also reported always or frequently using trastuzumab in an adjuvant  
(overall = 92%, U.S. = 93%, BRZ = 99%, MEX = 95%, TUR = 97%, RUS = 74%) and in a metastatic 
(overall = 92%, U.S. = 94%, BRZ = 100%, MEX = 93%, TUR = 98%, RUS = 73%) setting. 
Physicians in RUS reported more infrequent use of trastuzumab in these settings than physicians from 
any other country. 
Physicians who reported a score of 3 (not so often), 4 (rarely) or 5 (never) were asked to identify the 
reasons they did not use trastuzumab in different clinical settings (Table 2). Across all countries, the 
most common barriers to the use of trastuzumab in a neoadjuvant setting were related to insurance 
coverage, availability of the drug, treatment guidelines, patient comorbidities and cost to the patient. 
The most common barriers to the use of trastuzumab in an adjuvant setting were related to availability 
of the drug, cost to the patient, patient comorbidities, clinical data, insurance coverage and treatment 
guidelines. The most common barriers to the use of trastuzumab in a metastatic setting were related to 
insurance coverage, availability of the drug and treatment guidelines. 
Table 2. Most common barriers to the use of trastuzumab (n (%) of physicians) a,b. 
In a Neoadjuvant Setting 
Overall 
(n = 137) 
U.S.  
(n = 45) 
BRZ  
(n = 15) 
MEX  
(n = 14) 
TUR  
(n = 13) 
RUS  
(n = 50) 
Not included in the formulary of drugs covered by 
patients’ insurance 
38 33 53 50 23 62 
Not available in the hospital/clinic where I practice 37 11 33 50 23 42 
Use not recommended by treatment guidelines or 
protocol I follow in this setting 
37 49 40 36 0 38 
Patient has medical issues why they cannot take the 
drug (e.g., cardiac) 
36 38 13 7 0 2 
High out-of-pocket treatment cost for patient 34 31 47 21 23 16 
In an Adjuvant Setting 
Overall 
(n = 41) 
U.S.  
(n = 14) 
BRZ  
(n = 1) 
MEX 
(n = 4) 
TUR  
(n = 2) 
RUS  
(n = 20) 
Not available in the hospital/clinic where I practice 44 21 0 50 0 65 
High out-of-pocket treatment cost for patient 42 29 100 25 0 55 
Patient has medical issues why they cannot take the 
drug (e.g., cardiac) 
39 29 0 25 0 45 
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Table 2. Cont. 
In an Adjuvant Setting 
Overall 
(n = 41) 
U.S.  
(n = 14) 
BRZ  
(n = 1) 
MEX 
(n = 4) 
TUR  
(n = 2) 
RUS  
(n = 20) 
Use not supported by clinical trial data in this setting 39 64 0 50 100 15 
Not included in the formulary of drugs covered by 
patients’ insurance 
37 36 100 50 50 50 
Use not recommended by treatment guidelines or 
protocol I follow in this setting 
32 50 0 25 0 25 
In a Metastatic Setting 
Overall 
(n = 39) 
U.S. 
(n = 12) 
BRZ  
(n = 0) 
MEX 
(n = 5) 
TUR  
(n = 2) 
RUS  
(n = 20) 
Not included in the formulary of drugs covered by 
patients’ insurance 
49 42 0 20 0 40 
Not available in the hospital/clinic where I practice 44 42 0 20 0 65 
Use not recommended by treatment guidelines or 
protocol I follow in this setting 
41 25 0 20 50 25 
a Percentages based only on those physicians who reported that they not so often, rarely or never use 
trastuzumab. See “n” in each column for the number of physicians used to calculate percentages. b Barriers 
reported by >10% of these physicians across all markets. U.S., United States; BRZ, Brazil; MEX, Mexico; 
TUR, Turkey; RUS, Russia. 
Nearly one-third of all physicians, and a higher percentage in MEX, BRZ and RUS, answered yes to 
the question “are there any instances where you have not been able to treat a patient with trastuzumab or 
have had to delay their treatment due to reimbursement issues” (overall = 31%, U.S. = 10%, BRZ = 
48%, MEX = 37%, TUR = 16%, RUS = 76%). The most common reasons for this inability to use 
trastuzumab or delay in treatment are presented in Table 3. Reimbursement issues were encountered 
across all clinical settings (overall: neoadjuvant = 28%, adjuvant = 39%, metastatic = 32%). The most 
common setting where reimbursement issues were encountered was the metastatic setting in the U.S. 
(60%) and the adjuvant setting in all other countries (BRZ = 39%, Mexico = 43%, TUR = 33%,  
RUS = 47%). 
Table 3. Most common reasons physicians had to cancel or delay treatment with 
trastuzumab (% of physicians) a. 
Reasons for Cancel or Delay 
Overall 
(n = 153) 
U.S.  
(n = 20) 
BRZ  
(n = 36) 
MEX  
(n = 28) 
TUR  
(n = 12) 
RUS  
(n = 57) 
Patient had no insurance/not eligible for reimbursement 28 32 22 32 39 25 
Insurance/government refused to fund the treatment 27 32 64 11 24 10 
Hospital did not have funds to provide trastuzumab 26 10 8 33 8 44 
Patient unable to pay copayment 15 14 6 22 15 16 
Other 4 12 0 2 14 5 
a Based only on those physicians who reported having to cancel or delay treatment with trastuzumab. U.S., 
United States; BRZ, Brazil; MEX, Mexico; TUR, Turkey; RUS, Russia. 
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3.4. Impact of a Biosimilar to Trastuzumab 
Across all markets, 45% of physicians reported that they would increase the use of HER2 antibody 
therapy if a lower cost biosimilar version of trastuzumab were available (U.S. = 29%, BRZ = 53%,  
MEX = 63%, TUR = 23%, RUS = 81%). This trend was observed across all clinical settings (Table 4). 
Among physicians who said a biosimilar version would not increase their use of HER2 antibody therapy, 
the most common reason was reported as “already always use it in all the appropriate patients/situations” 
(overall = 35%). 
Table 4. Percentage of physicians who would increase their use of HER2 antibody therapy 
in different clinical settings if a biosimilar to trastuzumab were available a. 
 Overall 
(n = 223) 
U.S.  
(n = 58) 
BRZ  
(n = 40) 
MEX  
(n = 47) 
TUR  
(n = 17) 
RUS  
(n = 61) 
Neoadjuvant setting 46 52 33 53 71 38 
Adjuvant setting       
Duration >6 months 45 45 53 43 59 38 
Metastatic setting       
1st line 50 53 43 53 53 48 
2nd line 50 59 38 32 71 57 
a Based only on those physicians who reported potential increased use of HER2 antibody therapy if a 
biosimilar were available. U.S., United States; BRZ, Brazil; MEX, Mexico; TUR, Turkey; RUS, Russia. 
4. Discussion 
This study demonstrates that there are barriers to the use of trastuzumab across the globe due to 
several physician-identified factors, including access to and cost of treatment. However, almost half of 
physicians surveyed indicated that the use of HER2-directed therapies would increase with the 
availability of a lower cost biosimilar HER2 monoclonal antibody. 
The healthcare systems for the countries included in this study are varied, though they each offer 
both government-subsidized and private coverage options for their citizens. The Turkish system is 
predominantly government-based and managed by the Ministry of Health, though reforms over the 
past decade have resulted in modestly increased access to private healthcare coverage [17]. Centralized 
coverage is funded by a social security system that is based on employee, employer and government 
contributions [17]. In addition, low income citizens receive free basic coverage under the Green Card 
Scheme [17]. RUS also has a predominantly state-run system, managed by the Ministry of Health and 
Social Development, which mandates nominally free basic healthcare for all citizens [18]. Funding for 
this system results from a relatively even mix of tax revenues, payroll contributions and out-of-pocket 
payments for uncovered services (such as outpatient prescription medicines) [18]. BRZ mandates 
universal free healthcare for its citizens that is funded at the federal, state and local levels [19]. 
However, as a result, quality of care varies greatly in different regions of BRZ, and approximately 25% 
of Brazilians opt to purchase private medical insurance [19]. The Mexican healthcare system is also a 
mix of government-subsidized (amount of subsidy based on patient income level) and private  
coverage [20]. The U.S. healthcare system is based largely on private insurance coverage, purchased 
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by the patient, though government-subsidized options are available to older citizens, citizens with 
certain disabilities and citizens with low income. Recent healthcare reform in the U.S. requires most 
citizens to purchase some form of basic healthcare coverage [21]. 
Despite different healthcare systems, barriers to the use of trastuzumab were identified in every 
country examined. Though the study was not powered to directly compare different countries, certain 
assumptions can be made based on the data presented. BRZ, for example, had the least number of 
patients with government-funded healthcare and the greatest number of patients having to pay for private 
medical insurance on their own. Likely because of this, physicians from BRZ most often cited “high  
out-of-pocket costs for the patient” as a barrier to the use of trastuzumab. Though ~70% of patients in 
MEX and RUS had government-funded healthcare, physicians in these countries most often reported 
that trastuzumab was “not available in the hospital/clinic where they practice” or “not included in  
the formulary of drugs covered by patient’s insurance” as barriers to the use of trastuzumab.  
Not surprisingly, physicians from BRZ, MEX and RUS most often reported having to cancel or delay 
treatment with trastuzumab due to reimbursement/payment issues. Even in the U.S., where private 
medical insurance is predominate, physicians commonly reported “high out-of-pocket costs for the 
patient”, trastuzumab “not being included in the formulary of drugs covered by patient’s insurance” or 
trastuzumab “not being available in the hospital/clinic where they practice” as barriers to the use of 
trastuzumab. Overall, these data demonstrate that the cost of treatment is a significant barrier to the 
access and use of trastuzumab. In addition, clinical treatment guidelines were often cited as a barrier to 
the use of trastuzumab, particularly in an adjuvant or metastatic treatment setting. 
The costs of cancer care are increasingly becoming important to the U.S. payer system, as cost 
containment is a key component of the Affordable Care Act [15]. A study comparing the treatment 
cost of biosimilars vs. innovator biologic for five common treatments in India estimated that the use of 
biosimilars would result in yearly savings of ~843 million U.S. dollars [22]. Reditux™ (Dr. Reddy’s 
Laboratories, Hyderabad, India), for example, the first intended biosimilar to the monoclonal anti-CD20 
cancer agent rituximab, was launched in India in 2007 at 50% lower cost than the originator biologic 
(MabThera™®, Hoffman-LaRoche, Basel, Switzerland). As a result, patient access to CD-20-directed 
therapy increased six-fold within three years of launch [23]. Likewise, the availability of a trastuzumab 
biosimilar may alleviate the cost-related barriers to the access and use of HER2 antibody therapy. Many 
oncologists clearly understand the cost benefit of biosimilars, as a majority of those surveyed from the 
U.S. and the EU expect to prescribe biosimilars to common monoclonal antibody treatments within the 
first 12 months of their launch [24]. 
In addition to HER2+ breast cancer patients, other patient populations may also benefit from  
the availability of a biosimilar to trastuzumab. Trastuzumab is also indicated for the treatment of 
HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, and its addition 
to chemotherapy significantly improves overall survival [25]. In the future, these patients may also 
benefit from the availability of a biosimilar to trastuzumab. However, the current study does not 
address the use of trastuzumab or the availability of a biosimilar in these malignancies. 
All survey research, including the current study, is limited in some way. For example, respondents 
(physicians in this case) may not precisely recall experiences in the past. Additionally, the survey 
question regarding the use of a potential biosimilar to trastuzumab is limited in that it does not specify 
exactly how much less expensive the biosimilar would be compared to Herceptin®. In order to achieve 
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our survey responder goal of 500 physicians (200 U.S. and 75 each in MEX, BRX, RUS and TUR), 
nearly 8,000 total physicians were invited to participate. It is possible that our findings are subject to 
non-responder bias, since a majority of invited physicians did not participate or were unable to 
participate due to closure of the survey once the responder goal was reached. Though the physicians and 
countries included in this survey vary in their geographic, economic, cultural and healthcare 
environment, care must be taken when attempting to generalize our findings to physicians from 
countries outside the scope of this study. 
5. Conclusions 
Innovations in cancer therapy are costly and contribute to rising healthcare expenditures. Improved 
accesses to therapies and novel delivery models have the potential to advance the prevention and 
treatment of cancer. The introduction of high-quality biosimilars could potentially benefit patients by 
broadening access to alternative biologic therapies. In this study, we conclude that there are significant 
barriers to the use of trastuzumab and that a biosimilar to trastuzumab could increase access to and use 
of HER2-directed antibody therapy in patients with HER2+ breast cancer. 
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